PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need.
The company’s most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020.
The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US.
PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019.
- protects the peripheral nerves
Protection against the nerve damage that often occurs in connection with chemotherapy.
- protects the liver
Prevents acute liver failure in paracetamol poisoning.